ArcherDX | Evaluate

It takes more than a pandemic to stop medical device companies merging.

The first pan-cancer approval might have gone to Guardant, but Roche’s subsidiary’s blood test appears to be able to find more markers.

July 09, 2020

2019 was an average year for medtech M&A. 2020, not so much.

June 23, 2020

The cash-and-stock deal, worth $886m up front, is the first major liquid biopsy acquisition since Roche bought Foundation Medicine.

Evaluate